Provectus Biopharmaceuticals, Inc.
PVCT
$0.05
$0.00-0.75%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -91.26% | -45.54% | -51.60% | -32.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -91.26% | -45.54% | -51.60% | -32.72% |
| Cost of Revenue | -54.81% | -2.65% | -7.36% | 16.31% | 25.18% |
| Gross Profit | 42.81% | -48.86% | -10.24% | -61.38% | -62.23% |
| SG&A Expenses | -18.43% | -5.59% | 34.38% | 303.38% | 302.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.34% | -4.76% | 16.17% | 126.66% | 128.26% |
| Operating Income | 25.89% | -7.16% | -25.83% | -186.07% | -181.73% |
| Income Before Tax | 25.59% | -4.15% | -15.60% | -122.35% | -130.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.59% | -4.15% | -15.60% | -122.35% | -130.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -64.19% | 23.87% | 151.01% | -- | -- |
| Net Income | 25.04% | -3.96% | -14.76% | -119.02% | -127.10% |
| EBIT | 25.89% | -7.16% | -25.83% | -186.07% | -181.73% |
| EBITDA | 25.88% | -7.24% | -26.01% | -187.16% | -182.77% |
| EPS Basic | 24.67% | -4.72% | -15.18% | -118.06% | -127.27% |
| Normalized Basic EPS | 25.00% | -5.41% | -22.58% | -161.11% | -158.82% |
| EPS Diluted | 24.67% | -4.72% | -15.18% | -118.06% | -127.27% |
| Normalized Diluted EPS | 25.00% | -5.41% | -22.58% | -161.11% | -158.82% |
| Average Basic Shares Outstanding | 0.02% | 0.07% | 0.11% | 0.16% | 0.16% |
| Average Diluted Shares Outstanding | 0.02% | 0.07% | 0.11% | 0.16% | 0.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |